Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: Sandoz Enbrel Copycat Next Biosimilar To Get Panel Treatment <i>(Scrip)</i>

PRESS: Sandoz Enbrel Copycat Next Biosimilar To Get Panel Treatment (Scrip)

Related Content

The Court of Appeals for the Federal Circuit’s In Re Riggs Decision: 35 USC 102(e) Prior Art Requires Written Description Support in Provisional Application for Disclosure Relied On to Reject Claims

The Court of Appeals for the Federal Circuit’s In Re Xencor Decision: Jepson Claims Require Written Description for Their Preambles

Second Circuit Sees Eye to Eye With Warby Parker in Trademark Google Ads Dispute

Four Steps to Maximize the Value of AI Innovation in Medtech

Are AI Inventions Harder to Patent?

FDA Platform Technology Draft Guidance Highlights Utility of Obscure Patent Term Extension Provision

USPTO Issues Further Guidance on AI-Related Patent Eligibility

The Rapid Rise of AI, in Five Charts

EcoFactor v Google Unlikely to Result in ‘Tectonic Shifts in the Law’ (World IP Review)

Neel Chatterjee and Brett Schuman Recognized by Daily Journal’s Top IP Lawyers 2025

The Legal 500 EMEA 2025 Recognizes Goodwin for Excellence Across Europe

Leading the Charge in Life Sciences Litigation, Goodwin is Shortlisted For Three Managing IP Awards

Judge Denies Post-Trial Motions in Chip Designers' M&A Row, Bringing Judgment to More Than $41 Million (The Recorder)

Chambers Global 2025 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders

Goodwin Named a Top Firm in World Trademark Review for the Tenth Consecutive Year

Goodwin Adds NY IP Attys (Law360)

Life Sciences

Intellectual Property

Complex Litigation & Dispute Resolution

Hatch-Waxman, Biologics and Biosimilars Litigation

Life Sciences Regulatory & Compliance

Litigation